Form 8-K - Current report:
SEC Accession No. 0001087294-25-000012
Filing Date
2025-10-21
Accepted
2025-10-21 09:25:32
Documents
14
Period of Report
2025-10-21
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20251021.htm   iXBRL 8-K 27505
2 EX-99.1 cumberlandtaliciaannouncem.htm EX-99.1 29997
6 image_0.jpg GRAPHIC 18991
  Complete submission text file 0001087294-25-000012.txt   207177

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20251021.xsd EX-101.SCH 1894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20251021_lab.xml EX-101.LAB 21900
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20251021_pre.xml EX-101.PRE 12611
16 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20251021_htm.xml XML 2828
Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 621765329 | State of Incorp.: TN | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 251405525
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)